Post Covid-19 Dysautonomia Rehabilitation Randomized Controlled Trial
- Conditions
- DysautonomiaPost-Acute COVID-19 Syndrome
- Interventions
- Procedure: RehabilitationProcedure: Standard of Care
- Registration Number
- NCT05855356
- Lead Sponsor
- Evangelismos Hospital
- Brief Summary
Dysautonomia in post-covid-19 condition appears to affect a significant number of patients, with reports raising the incidence up to 61%, having an overlap with myalgic encephalomyelitis/ chronic fatigue syndrome. Quality of life and daily function is significantly impacted and conservative management interventions, despite the lack of high quality evidence up to now, are needed to ameliorate disability. 50 adults with a dysautonomia post-covid-19 diagnosis based on the Ewing battery and a NASA lean test will be enrolled in a randomized single blinded controlled trial with a crossover design. Feasibility and lack of definite dysautonomia diagnosis will be the primary out-comes, while secondary outcomes will be health-related, clinical and cardiopulmonary exercise test indicators. Safety and acceptance will also be checked, primarily excluding participants with post exertional malaise. The Long-CoViD patients Causal Diagnosis and Rehabilitation study in patients with Dysautonomia (LoCoDiRE-Dys) study intervention will consist of an educational module, breathing retraining and an individualized exercise intervention of biweekly sessions for two months with regular assessment of both groups. LoCoDiRe- Dys aims to be the first post-covid-19 randomized study in people with dysautonomia offering a multimodal intervention both in diagnosis and management
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 50
- Adults 18-65 years of age
- WHO definition of post covid-19 condition
- Confirmed dysautonomia diagnosis through Ewing Battery
- Able to attend 2 times/ week for 8 weeks
- Able to provide informed consent
- Absolute or relative contra-indications to exercise due to cardiac pathology
- Serious mental/ cognitive impairment that will not allow systematic participation
- Unable to regularly reach the center
- Pregnancy
- CFS/ME fulfilling the Canadian Consensus Criteria
- Secondary health conditions that would explain symptoms, intervene in dysautonomia diagnosis or would impede participation in the exercise protocol (i.e. , untreated hypothyroidism and Diabetes Melitus, major psychiatric disorders, COPD, PICS, Pulmonary Fibrosis, chronic respiratory or heart failure, not ambulatory, suffering from dementia, chronically paralyzed, with paraplegia, with multiple injuries or other serious orthopedic problems that caused disability, patients suffering from very serious underlying diseases such as end-stage cancer, and those with neurological diseases causing disability)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description LoCoDiRe-Dys Rehabilitation Respiratory physiotherapy, personalized aerobic and strength training in parallel with standard of care LoCoDiRe-Dys Standard of Care Respiratory physiotherapy, personalized aerobic and strength training in parallel with standard of care Standard of Care Standard of Care Standard of care including behavioural and medical advice
- Primary Outcome Measures
Name Time Method Number of patients with lack of definite Dysautonomia Diagnosis 4 months Ewing Battery is a validated instrument to diagnose dysautonomia, with a definite diagnosis when 2 out of 4 heart rate tests are abnormal
Compliance, Adverse Events and Protocol Titration to examine feasibility of the trial 4 months Process measures that will substantiate offering of the service
- Secondary Outcome Measures
Name Time Method 1 minute sit to stand test checked at [0], [8] and [16] weeks Validated measure to record the times standing up from a chair, closely related with cardiorespiratory capacity and lower limb strength
Fatigue Severity Scale checked at [0], [8] and [16] weeks Validated measure to record fatigue severity as reported by the patient, 9 statements each in a scale of 1-7, min 9 max 63
10 minutes NASA Lean Test checked at [0], [8] and [16] weeks Validated measure to record orthostatic intolerance, recording of blood pressure and heart rate in 5 min supine position, and every minute when standing up till 10 min
Six minute Walk Test checked at [0], [8] and [16] weeks Validated measure, a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
modified Medical Research Council Dyspnea Scale checked at [0], [8] and [16] weeks Validated measure to record functional disability because of dyspnea as reported by the patient in a scale 0-4
Nijmegen Questionnaire checked at [0], [8] and [16] weeks Validated measure to record dysfunctional breathing as recorded by the patient with each statement valued 0-4, with A score of over 23 out of 64 suggest a positive diagnosis of hyperventilation syndrome.
International Physical Activity Questionnaire checked at [0], [8] and [16] weeks Validated measure with 27 item self reporting physical activity of the patient
EuroQoL 5 Dimensions 5 Levels checked at [0], [8] and [16] weeks Validated measure, a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression
Cardiorespiratory exercise test checked at [0], [8] and [16] weeks A specialized type of stress test or exercise test that measures exercise ability
Montreal Cognitive Assessment checked at [0], [8] and [16] weeks Validated measure for rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation, with a normal score over 25/30
Hospital Anxiety and Depression Scale checked at [0], [8] and [16] weeks Validated measure, a 14-item measure designed to assess anxiety and depression symptoms in medical patients. Items are rated on a 4-point severity scale. The HADS produces two scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states. Scores of greater than or equal to 11 on either scale indicate a definitive case
Lower Extremity Strength checked at [0], [8] and [16] weeks Assessment of lower extremity strength using a dynamometer.
Trial Locations
- Locations (1)
First Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, National and Kapodistrian University of Athens
🇬🇷Athens, Attica, Greece